Catalent’s UpTempo Virtuoso™ AAV Platform

Published on: 

Sponsored Content

Catalent’s UpTempo Virtuoso™ AAV platform accelerates development, delivering clinical material in 9 months.

Catalent’s UpTempo Virtuoso™ adeno-associated virus (AAV) platform process accelerates timelines for gene therapy development and production of clinical material. With a simplified supply chain, increased development and manufacturing efficiencies, and standardized documentation, the scalable, CGMP-ready platform process can significantly reduce the time from gene to clinic. Catalent’s global network of dedicated, small- and large-scale clinical and commercial manufacturing facilities, can provide support to its partners at every stage of a candidate’s journey.